Prospective Grant of Co-Exclusive Option License: The Development of a Single Domain Human Anti-Mesothelin Monoclonal Antibody for the Treatment of Human Cancers
Citation: "79 FR 42025"
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, that the
The prospective co-exclusive (or exclusive) start-up option licensed territory may be worldwide, and the field of use may be limited to:
The use of the monoclonal antibody SD1 (and glycoengineered variants thereof) as an antibody therapy for the treatment of mesothelioma, pancreatic cancer, breast cancer, ovarian cancer and lung adenocarcinoma. The Licensed Field of Use explicitly excludes the use of the antibody in the form of an immunoconjugate, including, but not limited to, immunotoxins.
Upon the expiration or termination of the co-exclusive start-up option license,
DATES: Only written comments and/or applications for a license which are received by the
ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated co-exclusive start-up option license should be directed to:
SUPPLEMENTARY INFORMATION: This invention concerns a monoclonal antibody and methods of using the antibody for the treatment of mesothelin-expressing cancers, including mesothelioma, lung cancer, ovarian cancer and pancreatic cancer. The specific antibody covered by this technology is designated SD1, which is a single domain, fully human monoclonal antibody against mesothelin.
Mesothelin is a cell surface antigen that is preferentially expressed on certain types of cancer cells. The SD1 antibody can selectively bind to these cancer cells and induce cell death while leaving healthy, essential cells unharmed. This can result in an effective therapeutic strategy with fewer side effects due to less non-specific killing of cells.
The prospective co-exclusive start-up option license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404. The prospective co-exclusive start-up option license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404 within fifteen (15) days from the date of this published notice.
Complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated co-exclusive start-up option license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
[FR Doc. 2014-16853 Filed 7-17-14;
BILLING CODE 4140-01-P
Most Popular Stories
- Homeowners More Satisfied With Mortgage Servicers
- Russia, Ukraine Now Face Off Over Football Clubs
- Law Lets Users Unlock Cellphones
- Reno Gigafactory No Cinch to Land Tesla Plant
- Body Parts Retrieved at MH17 Crash Site
- Government Meets Goal for Small-business Contracts
- Motorists Get Rare Summer Break on Gas Prices
- Obama Vows to Veto House Immigration Bill
- Chrysler U.S. Sales in July Hit 9-Year High
- MassMutual Teams Up With ALPFA